The news of ARCALIS, a partner of Arcturus Therapeutics, receiving a substantial grant from the Japanese government is likely to be seen as a positive development for ARCT. This funding could potentially accelerate the development and production of their joint venture projects. Additionally, the achievement of a significant development milestone in their LUNAR-FLU collaboration with CSL Seqirus further indicates progress and potential future revenue. Both these factors are likely to have a positive impact on ARCT's stock in the short term.